Speciality Medicines Lists Flat at ₹124, Up 0.40%

Speciality Medicines Ltd, incorporated in 2021 engaged in marketing and distribution of finished formulations of speciality pharmaceuticals including high-cost oral and injectable medications for complex chronic conditions operating via contract manufacturing and marketing/distribution models with distribution network across 20+ states in India and 35+ countries with 7 products registered overseas and 54 products in registration process across Jordan, Ethiopia, Uganda, Peru, and Namibia, made a flat debut on BSE SME on Monday, March 30, 2026. The Speciality Medicines share price opened flat at ₹124.00 at issue price, touched high of ₹129.50 (up 4.44%) before trading around ₹124.50 (up 0.40%).

Speciality Medicines Listing Details

Speciality Medicines launched its IPO at ₹124 per share with minimum investment of 2,000 shares costing ₹2,48,000. The IPO received moderate response with subscription of 2.27 times - retail investors undersubscribed at 0.85 times, NII at 1.88 times (bNII at 2.50 times, sNII undersubscribed at 0.64 times), QIB strongly subscribed at 96.24 times, total applications of merely 688.

First-Day Trading Performance

Listing Price: Speciality Medicines stock price opened flat at ₹124.00 at issue price, touched high of ₹129.50 (up 4.44%) before trading around ₹124.50 (up 0.40%), with VWAP at ₹124.37. The flat listing reflected muted investor interest with turnover of ₹16.69 crore, traded volume of 13.42 lakh shares, and market capitalisation of ₹109.38 crore against pre-IPO market cap of ₹108.94 crore.

Growth Drivers and Challenges

Growth Drivers:

• Diversified Global Presence: Distribution network spanning 20+ states in India and 35+ countries worldwide with 7 products registered overseas and 54 products in registration process across Jordan, Ethiopia, Uganda, Peru, and Namibia enabling international expansion.
• Strong Financial Growth: Revenue growing from ₹27.66 crore in FY24 to ₹58.54 crore in FY25, PAT growing from ₹2.93 crore to ₹8.61 crore, healthy ROE of 18.11%, ROCE of 16.68%, PAT margin of 16.49% with low debt-to-equity of 0.13.
• Diversified Product Portfolio: Wide range of speciality pharmaceutical formulations including tablets, capsules, injectables, inhalers, nasal sprays, and ophthalmic solutions for complex chronic conditions.

Challenges:

• Sustainability Concerns: Analyst warns surge in profits from FY25 onwards raises eyebrows over sustainability with issue appearing lucratively priced due to higher profits shown for recent years.
• Weak Retail Interest: Only 688 total applications with retail undersubscribed at 0.85x and sNII at 0.64x.
• Small Scale Operations: Small equity base post-IPO indicates longer gestation period for mainboard migration, significant promoter dilution from 59.28% to 43.44%.

Utilisation of IPO Proceeds

R&D Centre: ₹12.68 crore for setting up Research and Development Centre at Valsad, Gujarat.

Working Capital: ₹8.00 crore for meeting working capital requirements.
Product Registration: ₹2.99 crore for product registration in international markets and product development.

Marketing: ₹1.66 crore for funding marketing and promotional activities.
General Corporate Purposes: ₹0.25 crore for general corporate purposes.

Financial Performance

Revenue: ₹36.93 crore for 7 months ended October 2025, ₹58.54 crore for FY25, significant growth from ₹27.66 crore in FY24, reflecting expanding speciality pharmaceutical marketing and distribution operations across domestic and international markets.

Net Profit: ₹6.06 crore for 7 months FY26, ₹8.61 crore in FY25, growth from ₹2.93 crore in FY24, with post-IPO EPS of ₹11.82 and P/E of 10.49x. Investors tracking Speciality Medicines share price should note the strong profitability growth driven by international expansion despite analyst concerns over profit sustainability.